Mirabegron 50mg

β3-adrenoceptor activation stimulates Gsα-mediated activation of adenylyl cyclase, increasing intracellular cAMP concentrations and downstream PKA signaling. This signaling cascade regulates UCP1-associated pathways, hormone-sensitive lipase (HSL) activation, PGC-1α-associated transcriptional programs, mitochondrial biogenesis mechanisms, and cellular energy expenditure pathways.

Mirabegron is frequently utilized as a selective β3-AR agonist in studies examining thermogenic signaling networks, receptor-mediated metabolic regulation, and adrenergic control of mitochondrial function.

Mirabegron demonstrates substantially greater affinity for β3-adrenoceptors than for β1- or β2-adrenoceptors in receptor-binding and functional signaling assays. This selectivity allows experimental effects observed at appropriate concentrations to be primarily attributed to β3-AR activation.

In studies requiring rigorous receptor-subtype attribution, selective β1- and β2-adrenoceptor antagonists are often incorporated to distinguish β3-mediated signaling from potential off-target adrenergic activity.

Mirabegron is one of the most extensively characterized selective β3-adrenoceptor agonists available for experimental investigation. Its well-defined receptor pharmacology, documented activation of β3-AR-dependent signaling pathways, and favorable subtype selectivity make it a valuable research tool for studies of adrenergic receptor signaling, G-protein-coupled receptor pharmacology, cAMP-mediated signal transduction, thermogenic pathway regulation, mitochondrial signaling networks, and comparative β-adrenoceptor subtype characterization.